Sign inJoin waitlistJoin the waitlist

SK

Suman Kambhampati

Physician · University of Kansas Hospital and Medical Center

Credentials: · · · · · ·

History

University of Kansas Hospital and Medical Center
2025–Present

Hematology and Medical Oncology
University of Illinois College of Medicine at Chicago
1999–2002
Internal Medicine
1996–1999
Karnatak Med Clg Karnatak Univ
1992–1996

Research

Retinoic acid signaling pathways in development and diseases
Review · Bioorganic & Medicinal Chemistry · 2014 · 207 citations
Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study
Journal of Clinical Oncology · 2023 · 173 citations
Boron chemicals in diagnosis and therapeutics
Review · Future Medicinal Chemistry · 2013 · 164 citations

Amit Verma
17 papers · 2 as a fellow
Leonidas Platanias
12 papers
PV
Peter Van Veldhuizen
9 papers
Siddhartha Ganguly
6 papers
SP
Simrit Parmar
6 papers · 4 as a resident
Guillermo Garcia-Manero
5 papers
Brian McClune
4 papers
Ghulam Mohyuddin
4 papers
Hagop Kantarjian
4 papers
Joseph McGuirk
4 papers
MT
Martin Tallman
4 papers
Saulius Girnius
4 papers

Grants

Benefit of Venetoclax Addition ("Benefit VA") in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Department of Veterans Affairs · I01
Contact PI · Kansas City Va Medical Center
2025–2030
Center for Cancer Experimental Therapeutics
National Center for Research Resources · P20
Project lead · $45.3K · University of Kansas Lawrence
2009–2010

Clinical trials

A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Principal investigator · Recruiting · Phase 2
VA Office of Research and Development
2025–2030
Phase I and II Study of Auranofin in Chronic Lymphocytic Leukemia (CLL)
Principal investigator · Completed · Phase 2
University of Kansas Medical Center
2011–2015
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2024–2032
Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
Site PI · Recruiting · Phase 3
Alliance for Clinical Trials in Oncology
2023–2038